The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system

Expert Review of Clinical Pharmacology

Volumn 4, Issue 2, 2011, Pages 275-289

  Engel, Abbi L ^a   Holt, Gregory E ^b   Lu, Hailing ^c  

^a BASTYR UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CpG; imiquimod; immune response; immunotherapy; pharmacokinetics; poly I:C; resiquimod; TLR agonist; Toll like receptor

Indexed keywords

[N[4 [4 AMINO 2 ETHYL 1H IMIDAZO(4,5C)QUINOLIN 1 YL]BUTYL]ETHANESULFONAMIDE; AGATOLIMOD; ANA 975; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GLYCOPROTEIN GP 100; IMIQUIMOD; LIPOPOLYSACCHARIDE; NY ESO 1 ANTIGEN; POLYINOSINIC POLYCYTIDYLIC ACID; RESIQUIMOD; RINTATOLIMOD; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; WART VIRUS VACCINE; ZYMOSAN;

ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; BREAST METASTASIS; CANCER GENE THERAPY; CANCER IMMUNIZATION; CHILL; CHRONIC FATIGUE SYNDROME; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOOD; FOOD DRUG INTERACTION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CARCINOMA; HEPATITIS C; HERPES SIMPLEX; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOREGULATION; KIDNEY DISEASE; LIVER DISEASE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MELANOAMELOBLASTOMA; MELANOMA; MESOTHELIOMA; MYCOSIS FUNGOIDES; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PHARMACOKINETICS; REVIEW; SKIN LYMPHOMA; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TOPICAL TREATMENT; UNSPECIFIED SIDE EFFECT; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRUS INFECTION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE SYSTEM; LIGANDS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 79952762940     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.11.5     Document Type: Review

References (136)

1. Kawai T, Akira S. The role of patternrecognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11(5), 373-384 (2010).
2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
3. Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410(6832), 1099-1103 (2001).
4. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663), 1529-1531 (2004).
5. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303(5663), 1526-1529 (2004).
6. Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA 101(15), 5598-5603 (2004).
7. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 408(6813), 740-745 (2000).
8. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27(2), 161-167 (2008).
9. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13(8), 859-875 (2008).
10. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196-200 (2002).
11. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 27(2), 190-199 (2008).
12. Dudek AZ, Yunis C, Harrison LI et al. First in human Phase I trial of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res. 13(23), 7119-7125 (2007).
13. Fletcher S, Steffy K, Averett D. Masked oral prodrugs of Toll-like receptor 7 agonists: a new approach for the treatment of infectious disease. Curr. Opin. Investig. Drugs 7(8), 702-708 (2006). Excellent review on the modifications of drugs for oral administration to be effective Toll-like receptor (TLR)-7 agonists.
14. Harrison LI, Astry C, Kumar S, Yunis C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J. Clin. Pharmacol. 47(8), 962-969 (2007). Covers the important distinction of administration route for the effectiveness of TLR agonist 852A with thorough pharmacokinetics data.
15. Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review. J. Cutan. Med. Surg. 8(5), 338-352 (2004).
16. Mchutchison JG, Bacon BR, Gordon SC et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46(5), 1341-1349 (2007).
17. Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005).
18. Manegold C, Gravenor D, Woytowitz D et al. Randomized Phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(24), 3979-3986 (2008).
19. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115(3), 739-746 (2005).
20. + T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer 126(4), 909-918 (2010).
21. + T cells. J. Leukoc. Biol. 78(6), 1273-1280 (2005).
22. + T cells in melanoma patients. J. Immunother. 31(8), 781-791 (2008).
23. Sogaard OS, Lohse N, Harboe ZB et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a Toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin. Infect. Dis. 51(1), 42-50 (2010).
24. Friedberg JW, Kim H, McCauley M et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood 105(2), 489-495 (2005).
25. Dubensky TW Jr, Reed SG. Adjuvants for cancer vaccines. Semin. Immunol. 22(3), 155-161 (2010).
26. Currie AJ, Van Der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW. Targeting the effector site with IFN-αβ-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J. Immunol. 180(3), 1535-1544 (2008).
27. Schmidt C. Immune system's Toll-like receptors have good opportunity for cancer treatment. J. Natl Cancer Inst. 98(9), 574-575 (2006).
28. Carpentier A, Metellus P, Ursu R et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a Phase II study. Neuro. Oncol. 12(4), 401-408 (2010).
29. Mariani CL, Rajon D, Bova FJ, Streit WJ. Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas. J. Neurooncol. 85(3), 231-240 (2007).
30. Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45(5), 932-943 (1994). Primary evaluation of the pharmacokinetics considering backbone alterations.
31. Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28(1), 7-16 (1995). Primary evaluation of the pharmacokinetics considering backbone alterations.
32. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl Acad. Sci. USA 96(16), 9305-9310 (1999).
33. Boggs RT, Mcgraw K, Condon T et al. Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 7(5), 461-471 (1997).
34. Krieg AM, Matson S, Fisher E. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 6(2), 133-139 (1996).
35. Pisetsky DS, Reich CF 3rd. Influence of backbone chemistry on immune activation by synthetic oligonucleotides. Biochem. Pharmacol. 58(12), 1981-1988 (1999).
36. Sester DP, Naik S, Beasley SJ, Hume DA, Stacey KJ. Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J. Immunol. 165(8), 4165-4173 (2000).
37. Link BK, Ballas ZK, Weisdorf D et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29(5), 558-568 (2006).
38. Readett D, Denis L, Krieg A, Benner R, Hanson D. PF-3512676 (CPG 7909) a Toll-like receptor 9 agonist - status of development for non-small cell lung cancer (NSCLC). Presented at: 12th World Congress on Lung Cancer. Seoul, Korea, 2-6 September 2007.
39. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 303(5665), 1818-1822 (2004).
40. Wilson KD, Raney SG, Sekirov L et al. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int. Immunopharmacol. 7(8), 1064-1075 (2007). Detailed evaluation of the pharmacokinetics and pharmacodynamics of lipoplexed CpG oligodeoxy nucleotides via intravenous and subcutaneous administration.
41. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. DOI: 10.1016/j.addr.2010.04. 009 (2010) (Epub ahead of print). Review of tumor-associated endothelial biology with ana lysis of mechanisms for increased depot in these inflamed tissues.
42. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev. 60(7), 795-804 (2008).
43. Yoshida H, Nishikawa M, Yasuda S et al. TLR9-dependent systemic interferon-β production by intravenous injection of plasmid DNA/cationic liposome complex in mice. J. Gene Med. 11(8), 708-717 (2009).
44. Mui B, Raney SG, Semple SC, Hope MJ. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther. 298(3), 1185-1192 (2001).
45. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79(11), 7269-7272 (2005).
46. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4(5), 393-403 (2003).
47. Hamzah J, Nelson D, Moldenhauer G, Arnold B, Hammerling GJ, Ganss R. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest. 118(5), 1691-1699 (2008).
48. Hamzah J, Altin JG, Herringson T et al. Targeted liposomal delivery of TLR9 ligands activates spontaneous anti-tumor immunity in an autochthonous cancer model. J. Immunol. 183(2), 1091-1098 (2009).
49. Lan T, Kandimalla ER, Yu D et al. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc. Natl Acad. Sci. USA 104(34), 13750-13755 (2007).
50. Scheel B, Braedel S, Probst J et al. Immunostimulating capacities of stabilized RNA molecules. Eur. J. Immunol. 34(2), 537-547 (2004).
51. Bourquin C, Schmidt L, Lanz AL et al. Immunostimulatory RNA oligonucleotides induce an effective anti-tumoral NK cell response through the TLR7. J. Immunol. 183(10), 6078-6086 (2009).
52. Hornung V, Guenthner-Biller M, Bourquin C et al. Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11(3), 263-270 (2005).
53. Miller D, Brinkworth M, Iles D. Paternal DNA packaging in spermatozoa: more than the sum of its parts? DNA, histones, protamines and epigenetics. Reproduction 139(2), 287-301 (2010).
54. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30(1), 1-7 (2000).
55. Dummer R, Hauschild A, Becker JC et al. An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 14(3), 856-864 (2008).
56. Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk. Lymphoma 46(6), 935-939 (2005).
57. Spaner DE, Shi Y, White D et al. A Phase I/II trial of TLR7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 24(1), 222-226 (2010).
58. Spaner DE, Shi Y, White D et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 20(2), 286-295 (2006).
59. Robinson RA, Devita VT, Levy HB, Baron S, Hubbard SP, Levine AS. A Phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J. Natl Cancer Inst. 57(3), 599-602 (1976).
60. Strayer DR, Carter WA, Brodsky I et al. A controlled clinical trial with a specifically configured RNA drug, poly(I). poly(C12U), in chronic fatigue syndrome. Clin. Infect. Dis. 18(Suppl. 1), S88-S95 (1994).
61. Gowen BB, Wong MH, Jung KH et al. TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules. J. Immunol. 178(8), 5200-5208 (2007).
62. Navabi H, Jasani B, Reece A et al. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27(1), 107-115 (2009).
63. Thompson KA, Strayer DR, Salvato PD et al. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur. J. Clin. Microbiol. Infect. Dis. 15(7), 580-587 (1996).
64. Sakurai F, Terada T, Maruyama M et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly I:poly C in a murine lung metastasis model. Cancer Gene Ther. 10(9), 661-668 (2003).
65. Jasani B, Navabi H, Adams M. Ampligen: a potential Toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27(25-26), 3401-3404 (2009).
66. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets 6(4), 223-235 (2007).
67. Witt PL, Ritch PS, Reding D et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res. 53(21), 5176-5180 (1993).
68. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob. Chemother. 48(6), 751-755 (2001).
69. Averett DR, Fletcher SP, Li W, Webber SE, Appleman JR. The pharmacology of endosomal TLR agonists in viral disease. Biochem. Soc. Trans. 35(Pt 6), 1468-1472 (2007).
70. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect. Dis. 1, 3 (2001).
71. Stockfleth E, Meyer T, Benninghoff B et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch. Dermatol. 138(11), 1498-1502 (2002).
72. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol. 50(5), 722-733 (2004).
73. Schulze HJ, Cribier B, Requena L et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled Phase III study in Europe. Br. J. Dermatol. 152(5), 939-947 (2005).
74. Ondo AL, Mings SM, Pestak RM, Shanler SD. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J. Am. Acad. Dermatol. 55(6), 1092-1094 (2006).
75. Soria I, Myhre P, Horton V et al. Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int. J. Clin. Pharmacol. Ther. 38(10), 476-481 (2000). Valuable data on the comparison of pharmacokinetic data between subcutaneous versus oral administration of imiquimod.
76. Benson N, De Jongh J, Duckworth JD et al. Pharmacokinetic-pharmacodynamic modeling of a interferon response induced by a Toll-like 7 receptor agonist in mice. Antimicrob. Agents Chemother. 54(3), 1179-1185 (2010).
77. Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME. A Phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br. J. Cancer 74(9), 1482-1486 (1996).
78. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22(13-14), 1799-1809 (2004).
79. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13(5), 552-559 (2007).
80. Chang BA, Cross JL, Najar HM, Dutz JP. Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 27(42), 5791-5799 (2009).
81. Pockros PJ, Guyader D, Patton H et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind Phase IIa studies. J. Hepatol. 47(2), 174-182 (2007).
82. 3M Pharmaceuticals Press Release. 3M provides update on IRM pharmaceutical platform: Lilly and 3M suspend resiquimod trials. 24 February 2003.
83. Zuany-Amorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat. Rev. Drug Discov. 1(10), 797-807 (2002).
84. Valins W, Amini S, Berman B. The expression of Toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll-like receptor modulators. J. Clin. Aesthet. Dermatol. 3(9), 20-29 (2010).
85. Harrison LI, Skinner SL, Marbury TC et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol. Res. 296(1), 6-11 (2004). This study provides useful information not only on the variables that influence topical dosing, but also important pharmacokinetics data.
86. Quirk C, Gebauer K, Owens M, Stampone P. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas. J. Dermatol. 47(4), 258-265 (2006).
87. Geisse JK, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J. Am. Acad. Dermatol. 47(3), 390-398 (2002).
88. Turza K, Dengel LT, Harris RC et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J. Cutan. Pathol. DOI: 10.1111/j.1600-0560.2009.01290.x (2009) (Epub ahead of print).
89. Abramovits W, Gupta AK. New therapy update: ALDARA (imiquimod cream, 5%). Skinmed. 3(4), 215 (2004).
90. Adams S, O'Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181(1), 776-784 (2008).
91. Valmori D, Souleimanian NE, Tosello V et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA 104(21), 8947-8952 (2007).
92. Daayana S, Elkord E, Winters U et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br. J. Cancer 102(7), 1129-1136 (2010).
93. Van Seters M, Van Beurden M, Ten Kate FJ et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N. Engl. J. Med. 358(14), 1465-1473 (2008).
94. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br. J. Dermatol. 156(2), 337-345 (2007).
95. Green DS, Dalgleish AG, Belonwu N, Fischer MD, Bodman-Smith MD. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br. J. Dermatol. 159(3), 606-614 (2008).
96. Redondo P, Del Olmo J, Lòpez-Dìaz de Cerio A et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J. Invest. Dermatol. 127(7), 1673-1680 (2007).
97. Balducci M, De Bari B, Manfrida S, D'agostino GR, Valentini V. Treatment of Merkel cell carcinoma with radiotherapy and imiquimod (Aldara): a case report. Tumori 96(3), 508-511 (2010).
98. Wu JJ, Huang DB, Tyring SK. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res. 64(2), 79-83 (2004).
99. Tomai M, Miller RL, Lipson KE, Vasilakos JP, Woulfe SL. Immune response modifiers: imiquimod and future drugs for modulating the immune response. Drug Discov. Today: Ther. Strateg. 3(3), 343-352 (2006).
100. Mark KE, Corey L, Meng TC et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195(9), 1342-1331 (2007).
101. Sauder DN, Smith MH, Senta-Mcmillian T, Soria I, Meng TC. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother. 47(12), 3846-3852 (2003).
102. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic Th1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 27(6), 460-471 (2004). Detailed comparison of pharmacokinetics data and immune activation between the two administration routes in a human trial is a good example for considering the effectiveness of a TLR agonist in immune therapy.
103. Tulic MK, Fiset PO, Christodoulopoulos P et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113(2), 235-241 (2004).
104. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518), 1247-1255 (2006).
105. Yamada K, Nakao M, Fukuyama C et al. Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Sci. 101(1), 188-195 (2010).
106. Senti G, Johansen P, Haug S et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a Phase I/IIa clinical trial. Clin. Exp. Allergy 39(4), 562-570 (2009).
107. Tse K, Horner AA. Update on Toll-like receptor-directed therapies for human disease. Ann. Rheum. Dis. 66(Suppl. 3), iii77-iii80 (2007).
108. Van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol. 27(1), 49-55 (2006).
109. Friedberg JW, Kelly JL, Neuberg D et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br. J. Haematol. 146(3), 282-291 (2009).
110. Simons MP, O'Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol. 26(4), 341-345 (2008).
111. Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 13(6), 1404-1408 (1995).
112. O'Donnell MA, Krohn J, Dewolf WC. Salvage intravesical therapy with interferon-α 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J. Urol. 166(4), 1300-1304, discussion 1304-1305 (2001).
113. Singh GP, Singh U, Diwedi US, Singh PB. BCG plus recombinant interferon α2b in superficial bladder cancer. Indian J. Urol. 17(2), 124-126 (2001).
114. Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J. Clin. Oncol. 28(28), 4324-4332 (2010).
115. Carpentier A, Laigle-Donadey F, Zohar S et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro. Oncol. 8(1), 60-66 (2006).
116. Gorski KS, Waller EL, Bjornton-Severson J et al. Distinct indirect pathways govern human NK-cell activation by TLR7 and TLR-8 agonists. Int. Immunol. 18(7), 1115-1126 (2006).
117. Stavrakoglou A, Brown VL, Coutts I. Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod. Br. J. Dermatol. 157(3), 620-622 (2007).
118. Pashenkov M, Goess G, Wagner C et al. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24(36), 5716-5724 (2006).
119. + T cells in the circulation but not in the tumor site. J. Immunol. 177(3), 1670-1678 (2006).
120. Development discontinued for ANA975, an early stage compound for treatment of Hepatitis C virus infection. Anadys Pharmaceuticals I. 2007 http://ir.anadyspharma.com/phoenix.zhtml?c=148908&p=irolnewsArticle&ID= 1032389&highlight=
121. Clinicaltrials.gov: Tumor and vaccine site with a Toll-like receptor agonist http://clinicaltrials.gov/show/NCT00960752
122. Clinicaltrials.gov: Multiple oral dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-04878691 www.clinicaltrials.gov/ct2/show/NCT00810758?term=NCT00810758&rank=1
123. Clinicaltrials.Gov: Immunevasion of human papillomavirus (HPV) in vulvar intraepithelial neoplasia 2/3 and anogenital warts and efficiency and mechanisms of imiquimod treatment www.clinicaltrials.gov/ct2/show/NCT00941811?term= NCT00941811&rank=1
124. Clinicaltrials.gov: Imiquimod for breast cancer patients with chest wall recurrence or skin metastases www.clinicaltrials.gov/ct2/show/NCT00899574?term= NCT00899574&rank=1
125. Clinicaltrials.gov: Imiquimod and laser therapy with or without a green dye in treating patients with stage III or stage IV melanoma that has spread to other parts of the skin www.clinicaltrials.gov/ct2/show/NCT00453050?term= NCT00453050&rank=1
126. Clinicaltrials.gov: Randomized, double blind, placebo-controlled topical resiquimod adjuvant for NY-ESO-1 protein vaccination www.clinicaltrials.gov/ct2/ show/NCT00821652?term=NCT00821652&rank=1
127. Clinicaltrials.gov: PhaseI/II study of URLC10-177 and TTK-567 peptide vaccine combined with CpG7909 in patients with esophageal cancer www.clinicaltrials.gov/ct2/show/NCT00669292?term=NCT00669292&rank=1
128. Clinicaltrials.gov: Study of combination treatment with IMO-2125 and ribavirin in naive hepatitis C-infected, genotype 1 patients www.clinicaltrials.gov/ct2/show/NCT00990938?term=NCT00990938&rank=1
129. Clinicaltrials.gov: Safety study of adjuvant vaccine to treat melanoma patients www.clinicaltrials.gov/ct2/show/NCT01079741?term=NCT01079741&rank=1
130. Clinicaltrials.gov: A trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve subjects with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) www.clinicaltrials.gov/ct2/show/NCT01040832?term=NCT01040832&rank=1
131. Clinicaltrials.gov: Placebo-controlled, dose-escalation study of the safety of IMO-2125 in hepatitis C-infected patients www.clinicaltrials.gov/ct2/ show/NCT00728936?term=NCT00728936&rank=1
132. Clinicaltrials.gov: Feasibility of autologous tumor cell-TLR9 agonist vaccination for metastatic colorectal cancer www.clinicaltrials.gov/ct2/show/ NCT00780988?term=NCT00780988&rank=1
133. Clinicaltrials.gov: A methodology study in healthy subjects to evaluate the effect of AZD8309 after nasal administration of lipopolysaccharide www.clinicaltrials.gov/ct2/show/NCT00860821?term=NCT00860821&rank=1
134. Clinicaltrials.gov: Phase I/II study of intratumoral injection of CPG 7909, a TLR9 agonist, combined with local radiation for patients with recurrent mycosis fungoides www.clinicaltrials.gov/ct2/show/NCT00226993?term= NCT00226993&rank=1
135. Clinicaltrials.gov: Phase I/II CPG 7909 + local XRT in recurrent low-grade lymphomas www.clinicaltrials.gov/ct2/show/NCT00185965?term= NCT00185965&rank=1
136. Clinicaltrials.gov: Safety study of SD-101 (a novel C type TLR9 agonist) for the treatment of chronic hepatitis C virus infection www.clinicaltrials.gov/ ct2/show/NCT00823862?term=NCT00823862&rank=1